Biotech Platforms

Sector thesis

Biotech platforms are companies that build the foundational tools and infrastructure other drug makers use to discover and develop medicines. Think of them as the "picks and shovels" of the biotech world—they don't necessarily make the final drug, but they enable others to do it faster and cheaper. This includes gene-editing systems (like CRISPR), AI-powered drug discovery software, contract research labs, and sequencing technologies. The megatrend here is simple: drug development is getting faster and more precise. As the cost of sequencing DNA has plummeted and computing power has exploded, biotech companies can now test thousands of drug candidates in silico (on computers) before touching a test tube. This efficiency is reshaping how medicines get made, and platform companies sit at the center of that shift. Within this sector, three sub-categories matter most: gene-editing and synthetic biology tools (the actual molecular scissors and construction kits); AI and computational drug discovery (software that predicts which molecules will work); and contract research services (outsourced labs that run experiments for smaller biotech firms). Each has different economics and risk profiles. The biggest risk is that these platforms are only valuable if their customers succeed. If drug pipelines dry up or regulatory approval rates fall, demand for these tools collapses. There's also intense competition—once a platform proves useful, rivals copy it quickly. And many platform companies are unprofitable, betting on future scale; if that scale doesn't materialize, losses can be steep. For a retail portfolio, platform plays work best as a satellite position—not core holdings. They're less volatile than single-drug biotech but riskier than pharma giants. Watch for signs of customer adoption (how many companies use their tools?) and whether the platform is moving toward profitability. These are long-term bets on the infrastructure of medicine, not quick trades.